# 3D Systems Corp: Form 10-Q for the period ended Mar 31, 2025

- Company: [3D Systems Corp](/companies/ddd.md) (CIK 910638)
- Form: 10-Q
- Filed: 2025-05-12
- Accepted by EDGAR: May 12, 2025, 17:12 ET
- Period: 2025-03-31
- Accession: 0000910638-25-000010
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/910638/000091063825000010/ddd-20250331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/910638/000091063825000010/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-01-01 to 2025-03-31 | $94.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-01-01 to 2025-03-31 | $61.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2025-01-01 to 2025-03-31 | $32.7m | us-gaap:GrossProfit |
| Research and development | 3 months, 2025-01-01 to 2025-03-31 | $19.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2025-01-01 to 2025-03-31 | $49.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-01-01 to 2025-03-31 | −$36.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2025-01-01 to 2025-03-31 | $671.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-01-01 to 2025-03-31 | −$37.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-01-01 to 2025-03-31 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-01-01 to 2025-03-31 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-01-01 to 2025-03-31 | 132,462,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2025-01-01 to 2025-03-31 | −$33.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2025-01-01 to 2025-03-31 | $2.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-03-31 | $135.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-03-31 | $401.9m | us-gaap:AssetsCurrent |
| Total assets | at 2025-03-31 | $583.4m | us-gaap:Assets |
| Current liabilities | at 2025-03-31 | $144.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-03-31 | $435.7m | us-gaap:Liabilities |
| Long-term debt | at 2025-03-31 | $212.3m | us-gaap:LongTermDebtNoncurrent |

## Management's discussion and analysis

As filed, 33,771 characters.

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our financial statements with a narrative from the perspective of management and is intended to help the reader understand the results of operations and financial condition of the Company. Our MD&A should be read in conjunction with our MD&A and Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Annual Report on Form 10-K") and our Consolidated Condensed Financial Statements as of and for the three months ended March 31, 2024 included in this Form 10-Q.

### Information Relating to Forward-Looking Statements

Certain statements contained in this MD&A may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed, or implied by, such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.

Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These factors include without limitation:

- impact on our business as a result of macroeconomic events and other geopolitical risks, recession, supply chain disruptions, inflation, interest rates and foreign exchange volatility;
- our ability to deliver products that meet changing technology and customer needs;
- our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;
- our ability to realize anticipated benefits for future dispositions;
- impact of future write-off or write-downs of goodwill and intangible assets;
- the concentration of revenue and credit risk exposure from our largest customer;
- our ability to acquire and enforce intellectual property rights and defend such rights against third-party claims;
- our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;
- failure of our information technology infrastructure or inability to protect against cyber-attack;
- our ability to predict quarterly sales and manage product inventory due to uneven sales cycle;
- our ability to generate net cash flow from operations;
- our ability to service our debt and ability to raise funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes in the case of a fundamental change;
- our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;
- fluctuations in our gross profit margins, operating income or loss and/or net income or loss;
- our ability to efficiently conduct business outside the U.S.;
- our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;
- our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;
- product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;
- our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;
- our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;
- disruption in our management information systems for inventory management, distribution, and other key functions;
- compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;
- our ability to maintain our status as a responsible contractor under federal rules and regulations;
- changes in, or interpretation of, tax rules and regulations;
- our inability to use a Form S-3 Registration Statement; and
- the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2024 Annual Report on Form 10-K and this Form 10-Q.

Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

### Business Overview

3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions and Industrial Solutions. We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve their overall total cost of operation. Our technologies and process knowledge enable over a million production parts to be made through additive manufacturing each day.

### Recent Developments and Updates Regarding Strategic Initiatives

### 2025 Restructuring Plan

In March 2025, the Company authorized the next phase of its multi-faceted cost savings and restructuring initiative (the “2025 Restructuring Plan”). The 2025 Restructuring Plan includes initiatives to deliver sustainable growth and profitability, enabled by a streamlining of both infrastructure and business processes, while consistently investing in core research and development activities to support long-term growth opportunities.

The Company expects to incur approximately $12 million to $20 million in pre-tax restructuring and other related costs by the end of the second fiscal quarter of 2026. The charges under the 2025 Restructuring Plan are expected to be primarily cash charges.

Additionally, in May 2025, the Company announced an incremental cost reduction initiative focused on labor force reductions in response to the uncertain macroeconomic environment that is expected to deliver significant cost savings in the second half of the year.

### Other Strategic Business Decisions and Cost Saving Initiatives

### Geomagic Divestiture

In December 2024, the Company entered into a definitive agreement with Hexagon AB for the sale of its Geomagic software business ("Geomagic"), which was included in our Industrial Solutions segment. On April 1, 2025, the Company completed the sale of Geomagic and received $119.4 million in cash, which reflected applicable purchase price adjustments under the Asset Purchase Agreement and Business Transfer Agreement. The Company estimates it will record a pre-tax gain of $125.3 million from the sale of Geomagic in the second quarter of 2025.

No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been presented as a discontinued operation in the accompanying condensed consolidated financial statements because the sale of Geomagic does not represent a strategic shift that will have a major effect on the Company’s operations.

### Background

We earn revenue from the sale of products and services through our Healthcare Solutions and Industrial Solutions segments. The product categories include 3D printers and corresponding materials, digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services categories include maintenance contracts and services on 3D printers, software maintenance, software as a service subscriptions and healthcare solutions services.

Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.

In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this MD&A, the price and mix effects relate to changes in revenue that are not able to be specifically attributed to changes in unit volume or changes in foreign exchange rates.

### RESULTS OF OPERATIONS

### Comparison of Results of Operations

*(in thousands)*

|  | Three Months Ended March 31, 2025 | March 31, 2024 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $94,540 | $102,905 | $(8,365) |
| Cost of sales | 61,851 | 61,983 | (132) |
| Selling, general and administrative expenses ("SG&A") | 49,769 | 57,304 | (7,535) |
| Research and development expenses ("R&D") | 19,683 | 23,480 | (3,797) |
| Loss from operations | $(36,763) | $(39,862) | $3,099 |

### Revenue

The following table sets forth changes in our revenue for the three months ended March 31, 2025.

*(Dollars in thousands)*

|  | Products |  | Services |  | Total |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue - three months ended March 31, 2024 | $64,051 |  | $38,854 |  | $102,905 |  |
| Change in revenue: |  |  |  |  |  |  |
| Volume | (5,709) | (8.9)% | 1,434 | 3.7% | (4,275) | (4.2)% |
| Price/mix | (2,884) | (4.5)% | — | —% | (2,884) | (2.8)% |
| Foreign currency translation | (735) | (1.1)% | (471) | (1.2)% | (1,206) | (1.2)% |
| Net change | (9,328) | (14.6)% | 963 | 2.5% | (8,365) | (8.1)% |
| Revenue - three months ended March 31, 2025 | $54,723 |  | $39,817 |  | $94,540 |  |

23

For the three months ended March 31, 2025, revenue decreased $8.4 million, or 8.1%, compared to the three months ended March 31, 2024. The decrease in revenue was primarily due to a decline in product revenue of $9.3 million driven by lower materials volume to customers in the dental, service bureaus, and jewelry markets and unfavorable price/mix which were partially offset by an increase in revenue from hardware systems. The decline in product revenue was partially offset by a $1.0 million increase in service revenue due to higher volume.

### Cost of sales and gross profit

For the three months ended March 31, 2025, cost of sales remained relatively flat at $61.9 million compared to $62.0 million for the three months ended March 31, 2024. Declines related to lower sales volumes and a decrease in the provision for inventory obsolescence were mostly offset by unfavorable price/mix.

For the three months ended March 31, 2025, gross profit decreased $8.2 million, or 20.1%, compared to the three months ended March 31, 2024. The decrease in gross profit was primarily due to a combination of lower sales volumes and price/mix headwinds.

### Selling, general and administrative expenses

For the three months ended March 31, 2025, selling, general and administrative expenses ("SG&A") decreased $7.5 million, or 13.1%, compared to the three months ended March 31, 2024. The year-over-year decline in SG&A was primarily due to:

- $5.7 million decrease in third-party service provider and consulting costs due to the increased cost to complete our fiscal 2023 audit during three three months ended March 31, 2024;
- $1.2 million decrease in amortization expense related to intangible assets due to lower intangible asset balances which were reduced by prior-year impairment charges; and
- $0.6 million decrease in compensation and benefits expense primarily related to lower stock-based compensation expense due to the timing of awards which was partially offset by increased incentive compensation.

### Research and development expenses

For the three months ended March 31, 2025, research and development expenses ("R&D") decreased $3.8 million, or 16.2%, compared to the three months ended March 31, 2024. The year-over-year decline in R&D was primarily due to:

- $3.5 million decrease in compensation and benefits expense and other R&D expenses primarily due to improved operating efficiency and cost reductions realized from our restructuring activities.

### Segment Results

*(in thousands)*

|  | Segment Revenue March 31, 2025 | March 31, 2024 | Change | Segment Gross Profit March 31, 2025 | March 31, 2024 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Healthcare Solutions | $41,316 | $45,413 | $(4,097) | $16,024 | $16,982 | $(958) |
| Industrial Solutions | 53,224 | 57,492 | (4,268) | 16,665 | 23,940 | (7,275) |
| Total Company | $94,540 | $102,905 | $(8,365) | $32,689 | $40,922 | $(8,233) |

### Healthcare Solutions

#### Revenue

For the three months ended March 31, 2025, Healthcare Solutions revenue decreased $4.1 million, or 9.0%, compared to the three months ended March 31, 2024. The decrease in revenue was primarily due to a decline in product revenue of $6.1 million which was partially offset by an increase in service revenue of $2.0 million. The decline in product revenue was primarily due to lower sales in the dental market, including lower materials volume with a key customer. Service revenue increased due to growth in personalized healthcare solutions and parts manufacturing revenue.

#### Gross profit

For the three months ended March 31, 2025, Healthcare Solutions gross profit decreased $1.0 million, or 5.6%, compared to the three months ended March 31, 2024. The decrease in gross profit was primarily due to lower sales volumes.

### Industrial Solutions

#### Revenue

For the three months ended March 31, 2025, Industrial Solutions revenue decreased $4.3 million, or 7.4%, compared to the three months ended March 31, 2024. The decrease in revenue related to lower product and service revenue of $3.3 million and $1.0 million, respectively. The decline in product revenue was driven by lower materials sales to customers in the service bureaus and jewelry markets. The decline in service revenue was primarily due to decreases in hardware services and parts manufacturing revenue.

#### Gross profit

For the three months ended March 31, 2025, Industrial Solutions gross profit decreased $7.3 million, or 30.4%, compared to the three months ended March 31, 2024. The decrease in gross profit was primarily due to unfavorable price and mix and lower sales volumes.

### Non-operating income (expense)

The following table sets forth the components of non-operating income:

*(in thousands)*

|  | Three Months Ended March 31, 2025 | March 31, 2024 | Change |
| --- | ---: | ---: | ---: |
| Foreign exchange gain, net | $1,139 | $1,909 | $(770) |
| Interest income | 953 | 2,798 | (1,845) |
| Interest expense | (581) | (714) | 133 |
| Other (loss) income, net | (160) | 21,386 | (21,546) |
| Total non-operating income | $1,351 | $25,379 | $(24,028) |

#### Foreign exchange gain, net

Foreign exchange gain, net decreased by $0.8 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024, primarily due to realized and unrealized gains related to our foreign operations.

#### Interest income

Interest income decreased $1.8 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024, due to the Company's lower cash and cash equivalent balances.

#### Interest expense

Interest expense decreased $0.1 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024, due to lower debt issuance cost amortization on lower debt balances resulting from the repurchase of debt in the prior year.

#### Other (loss) income, net

Other (loss) income, net, decreased $21.5 million for the three months March 31, 2025 as compared to the three months ended March 31, 2024, primarily due to a gain on the repurchase of debt in the three months ended March 31, 2024.

### Income Taxes

For the three months ended March 31, 2025 and 2024, the Company’s effective tax rate was (1.9)% and (9.5)%, respectively. The differences between the U.S. statutory tax rate and the effective tax rates for the three months ended March 31, 2025 and 2024 were primarily driven by the recognition of a full deferred tax asset valuation allowance in various jurisdictions.

### Liquidity and Capital Resources

The following table sets forth the Company's operating working capital at March 31, 2025 and December 31, 2024.

*(in thousands)*

|  | March 31, 2025 | December 31, 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cash and cash equivalents | $135,040 | $171,324 | $(36,284) | (21.2)% |
| Accounts receivable, net | 104,691 | 101,471 | 3,220 | 3.2% |
| Inventories | 120,045 | 118,530 | 1,515 | 1.3% |
|  | 359,776 | 391,325 | (31,549) | (8.1)% |
| Less: |  |  |  |  |
| Current operating lease liabilities | 11,775 | 9,514 | 2,261 | 23.8% |
| Accounts payable | 39,767 | 41,833 | (2,066) | (4.9)% |
| Accrued and other liabilities | 44,310 | 45,488 | (1,178) | (2.6)% |
|  | 95,852 | 96,835 | (983) | (1.0)% |
| Operating working capital | $263,924 | $294,490 | $(30,566) | (10.4)% |

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements, excluding acquisitions, primarily consist of funding working capital and capital expenditures. Differences between the amounts of working capital item changes in the cash flow statement and the balance sheet changes for the corresponding items are primarily the result of foreign currency translation adjustments, acquisitions and divestitures.

At March 31, 2025, cash and cash equivalents totaled $135.0 million and decreased $36.3 million since December 31, 2024. This decrease resulted primarily from cash used in operations of $33.8 million and capital expenditures of $2.8 million.

Cash held outside the U.S. at March 31, 2025 was $58.2 million, or 43.1% of total cash and cash equivalents, compared to $63.8 million, or 37.3% of total cash and cash equivalents, at December 31, 2024. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. (e.g., via dividends) would not incur significant federal and state taxes. However, these dividends would be subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limit exposure to any one issuer depending upon credit quality. See “Cash Flow” discussion below.

### Cash Flow

The Company currently funds its operations, including working capital and capital expenditures, and acquisitions through cash on hand, cash equivalents, and financing activities as necessary. We expect that cash, cash equivalents, and other sources of liquidity, such as issuing equity, equity-linked, and/or debt securities, subject to market conditions, will be available and sufficient to meet our anticipated cash requirements. The following is a summary of the changes in the Company’s cash flows followed by a brief discussion of these changes:

*(in thousands)*

|  | Three Months Ended March 31, 2025 | March 31, 2024 | Dollar Change |
| --- | ---: | ---: | ---: |
| Cash flow used in operating activities | $(33,786) | $(25,545) | $(8,241) |
| Cash flow used in investing activities | (3,412) | (3,187) | (225) |
| Cash flow used in financing activities | (649) | (89,187) | 88,538 |

### Operating Activities

Cash flows used in operating activities were $33.8 million during the three months ended March 31, 2025, an increase of $8.2 million, as compared to the three months ended March 31, 2024. The year-over-year change in operating cash flows was primarily attributable to the following factors:

- Year-over-year decrease of $6.5 million in operating cash flows from net earnings, net of non-cash items.
- The aggregate changes in trade accounts receivable, inventory, and trade accounts payable used $5.9 million of cash during the three months ended March 31, 2025 as compared to using $11.1 million during the prior year comparable period. The amount of cash flow generated from or used by the aggregate of trade accounts receivable, inventories, and trade accounts payable depends upon how effectively we manage the cash conversion cycle, which generally represents the number of days that elapse from the day we pay for the purchase of raw materials and components to the collection of cash from our customers, and can be significantly impacted by the timing of collections and payments in a period.
- The aggregate change in prepaid expenses, other assets, accrued expenses, and other liabilities used $7.8 million in the three months ended March 31, 2025 as compared to using $0.9 million in the comparable period in the prior year comparable period. The year-over-year changes were driven by the timing of accruals and payments and tax-related amounts.

### Investing Activities

Net cash used in investing activities was $3.4 million during the three months ended March 31, 2025, a decrease of $0.2 million, as compared to the three months ended March 31, 2024, driven primarily by a decrease in purchases of property and equipment of $0.4 million, which was partially offset by an increase in our Enhatch investment of $0.6 million.

### Financing Activities

Net cash used in financing activities was $0.6 million during the three months ended March 31, 2025, a decrease of $88.5 million, as compared to the three months ended March 31, 2024, driven primarily by repayments of long-term debt of $87.2 million and a decrease in taxes paid related to net-share settlement of equity awards of $1.4 million in the prior year period.

### Material Cash Requirements

The Company's material cash requirements consist of the following contractual and other obligations:

#### Indebtedness

At March 31, 2025, we had $214.4 million of outstanding 0% convertible notes which mature in November of 2026. Management may consider pursuing additional long-term financing if it is appropriate in light of cash requirements for operations or strategic opportunities, which could result in higher financing costs.

#### Purchase Commitments

We have purchase commitments under legally enforceable agreements for goods and services with defined terms as to quantity, price and timing of delivery. The Company has certain purchase commitments under agreements with remaining terms in excess of a year, which primarily relate to printer assemblies, inventory, capital expenditures, and software licenses. As of March 31, 2025, such purchase commitments totaled $14.4 million, with approximately $8.1 million, expected to be due within the next twelve months.

#### Leases

The Company had operating and financing lease obligations (inclusive of interest) of $98.0 million at March 31, 2025, primarily related to real estate and equipment leases, of which approximately $18.2 million in payments are expected over the next twelve months.

#### Sources of Funding to Satisfy Material Cash Requirements

The Company believes that it has the financial resources needed to meet its anticipated cash requirements during the next twelve months. Cash requirements for periods beyond the next twelve months will depend on, among other things, the Company’s profitability and its ability to manage working capital requirements.

### Other Contractual Commitments

#### Indemnification

In the normal course of business we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.

To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.

### Critical Accounting Estimates

Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

### Goodwill & other long-lived assets, including intangible assets

#### Long-lived assets, including intangible assets

We review long-lived assets (or asset groups), including intangible assets subject to amortization, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset (or asset group) may not be recoverable. We assess the recoverability of the carrying value of assets (or asset groups) held for use based upon a review of undiscounted projected cash flows. Impairment losses, where identified, are measured as the excess of the carrying value of a long-lived asset (or asset group) over its estimated fair value, as determined using discounted projected cash flows. Our estimation of discounted projected cash flows requires us to make certain assumptions, including long-term revenue and expense forecasts, profit margins, discount rates and terminal growth rates.

#### Goodwill

Goodwill represents the amount by which the purchase price paid to consummate a business combination exceeds the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in the business combination. Goodwill is required to be assigned to a reporting unit for purposes of subsequent measurement and, as of March 31, 2025 and December 31, 2024, all of our reported goodwill was assigned to our Healthcare reporting unit.

We assess goodwill for impairment at least annually and, between annual impairment assessments, when circumstances indicate that there is a likelihood of greater than 50% that the carrying value of a reporting unit, inclusive of any assigned goodwill, exceeds the reporting unit’s fair value. On a forward-looking basis, such circumstances may include (1) a significant and sustained decrease in the trading price of our common stock that may suggest that the fair value of the Company and, accordingly, the fair value of our Healthcare reporting unit has declined, (2) a significant adverse change in the business climate for our Healthcare reporting unit, (3) a significant adverse change in the performance of our Healthcare reporting unit and/or (4) a decision to dispose of a significant portion of our Healthcare reporting unit.

When required to be performed, a quantitative goodwill impairment test compares the carrying value of a reporting unit to its fair value, and a goodwill impairment charge results when the reporting unit’s carrying value exceeds its fair value. The performance of a quantitative goodwill impairment test requires management to apply significant estimates and judgment – particularly to (1) estimate the fair value of the Company and each of our reporting units and (2) determine the carrying value of each of our reporting units, since we do not maintain separate balance sheets for our reporting units.

We estimate the fair value of our reporting units based primarily upon discounted cash flow projections for their underlying operations, which requires us to make significant assumptions regarding estimated cash flows, including long-term revenue and expense forecasts, profit margins, discount rates and terminal growth rates. We develop these assumptions based on the market risks unique to each reporting unit. In addition to the use of discounted cash flow projections, when appropriate, our estimates of the fair values of our reporting units include the results of applying the guideline company valuation method, which is a market approach. The application of the guideline company valuation method requires us to make judgments regarding (1) the appropriate set of comparable publicly traded guideline peer companies for which observable market multiples should be considered and (2) the appropriate multiple(s) to select from the range of multiples that may be observed for those guideline companies. We separately use reasonable and consistent allocation methodologies and approaches to allocate asset and liability balances to our reporting units when an account balance is not directly attributable to a specific reporting unit.

The remaining goodwill assigned to our Healthcare reporting unit could become subject to impairment upon any decrease in the estimated fair value of the Healthcare reporting unit or any increase in the estimated carrying value of the Healthcare reporting unit. Accordingly, over time, the key estimates, assumptions, and judgments that were used to estimate the fair value of our Healthcare reporting unit may change due to factors such as changes in market conditions and/or the actual performance of our Healthcare reporting unit. Similarly, over time, the carrying value of our Healthcare reporting unit could increase due to factors such as capital expenditures and/or the composition of the assets and liabilities of the Company and the underlying process and estimates required to allocate assets and liabilities that are not directly attributable to a specific reporting unit between/amongst our reporting units. Any unfavorable changes to the key estimates, assumptions, judgments or inputs utilized in our most recent quantitative goodwill impairment test – either on an individual basis or in the aggregate – could result in the recognition of impairment charges in the future.

There have been no material changes to our critical accounting estimates described in our 2024 Annual Report on Form 10-K.

## Market risk

As filed, 356 characters.

For a discussion of market risks at December 31, 2024, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2024 Annual Report on Form 10-K. During the three months ended March 31, 2025, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2024.

## Controls and procedures

As filed, 1,684 characters.

### Evaluation of Disclosure Controls and Procedures

As of March 31, 2025, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of March 31, 2025 due to the material weaknesses discussed in our 2024 Annual Report on Form 10-K.

### Changes in Internal Control Over Financial Reporting

We are in the process of implementing certain changes to our internal controls to remediate the material weaknesses described in our 2024 Annual Report on Form 10-K. Related to these efforts was the development of a remediation plan to specifically address processes and activities intended to rectify the issues identified as part of the material weaknesses. These plans include, but are not limited to, increased training, enhanced documentation associated with existing policies, and talent enhancements designed to specifically address the identified weaknesses. Aside from these activities, the results of which continue to be evaluated, there were no changes in the Company’s internal control over financial reporting during the three months ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 2,027 characters.

Information regarding risk factors appears in "Management's Discussion and Analysis of Financial Condition and Results of Operations - Information Relating to Forward Looking Statements," in Part I - Item 2 of this Form 10-Q and in "Risk Factors" in Part I - Item 1A of our 2024 Annual Report on Form 10-K. Except as set forth below, there were no material changes during the three months ended March 31, 2025 to the risk factors reported in our 2024 Annual Report on Form 10-K.

***Changes in U.S. trade policy and the impact of tariffs may have a material adverse effect on our business and results of operations.***

The U.S. has instituted or proposed changes in trade policies that include the imposition of higher tariffs on imports into the U.S. affecting trade between the U.S. and other countries where we conduct our business, such as China and certain European countries. The new tariffs and other changes in U.S. trade policy have and could continue to trigger retaliatory actions by affected countries, and foreign governments have imposed or are considering imposing trade sanctions on certain U.S. goods. Such actions have the potential to adversely impact the U.S. economy, our industry and the global demand for certain products, and as a result, could have a negative impact on our business, financial condition and results of operations.

Additionally, if the U.S. continues to affect changes to U.S. trade policy and impose such tariffs, this may cause supply chain disruptions and could further increase our costs. We may increase our sales prices in order to pass these increased costs to our customers, and our customers may, in turn, reduce their orders from us, which could negatively affect our business, profitability and operating results. While we are closely monitoring these developments and evaluating strategies to mitigate potential impacts, we may not be able to successfully mitigate the adverse impacts of these actions on our business and results of operations on a timely basis or at all.

Filed May 12, 2025.
Source: SEC EDGAR, the filing index for accession 0000910638-25-000010. Last ingested by Listed: Nov 15, 2026, 00:01 ET. No prices; not investment advice.
